|
The AdvoKat |
The Financial
Times today contains a review article about intellectual property and in particular considers the US’s inclination
to export its IP system to the world. The author, Alan Beattie, opens his
analysis by making reference to Washington delivering the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) in the 1990s and the
strong opposition to IP from developing countries which followed in the Doha Round of the World Trade Organization (WTO). The author then brings us up to date by reference to
“controversial” talks about IP taking place in the context of the TPP (Trans-Pacific Partnership) and that the US has pressed Chile to tighten its copyright
laws. The author also reminds us that a complaint
has been made by Ukraine, Honduras and the Dominican Republic against Australia
at the WTO in response to its decision to require cigarettes to be sold in
plain olive-green packaging.
Although the article lacks focus, the
impression one is left with is that the export of a US IP system to developing
countries is mostly a bad idea. The
article concludes, that few doubt there is a need for rules to protect IP but
that such rules are mainly being written by the beneficiaries ["And just who are these beneficiaries?", the IPKat wonders].
|
Although the balancer of life, the Greek Goddess, Nemesis, would find difficulty finding the creators of balance in the IP system |
Articles like this are an easy target for
criticism. There is however a point worthy of serious consideration. We know
that monopoly rights are about balances between the need to protect ideas (for
moral and commercial reasons) and the need to allow ideas to flow freely.
Whether you are in Washington, Shenyang or Nairobi there is a balance to be
struck. International treaties and government legislation provide the necessary
framework for the existence and enforcement of IP rights but, other than
setting the length of those rights, they say little about where the balance
should be set in terms of breadth of protection. It is surely the breadth of IP
rights which is a crucial factor in determining the extent to which ideas are
allowed to flow through the economy. (For example, in patent law one gets
little assistance from the legislature as to how broad a patent claim can be
drawn if a novel gene or a novel chemical is identified; and in copyright one
gets little legislative guidance as to how much material has to be taken for
there to have been a copying.)
Decisions on such matters are made by courts
and patent and trademark offices. Such institutions build up a body of case law
and judges and hearing officers build up personal experience of what is acceptable.
But if not the legislature then what are the forces present at the macro level
which are directing courts and administrative bodies to find where the correct
balance lies? One might argue that ultimately it is the users – the monopolists
and infringers – who affect the setting of this balance. This argument would be
akin to the, now often criticised, ‘efficient market hypothesis’ in finance. On
the other hand is the setting of the balance nothing more than a collection of
largely subjective views which just happen to end up in a particular place?
When they wrote the European Patent Convention they decided that the balance should be between fair protection for the inventor's patentable contribution to the technical field and reasonable certainty for the public. I second that.
ReplyDeleteWhen the EPO got going, it decided that the scope of allowable claims should be no wider than commensurate with the size of the contribution to the art. I second that.
We see the same thing in design patents. What does it matter where in the patent world we are doing the balancing?
Not sure about trademarks though. Ideas? Contributions? Then again, an RTM lasts for ever.
Clearly TRIPs/WTO and the TPP are ways in which the developed world, and particularly the US, enforce their economic power. That's just part of life. However I think that there are clearly advantages for countries to use legislation written in the US (or Europe for that matter) since good legislation ought to preempt and deal with possible problems that arise. With reference to how broad claims should be for new genes or chemicals, clearly EPO case law is available for the world to see, and it does seem to be influential around the world. The developing world is always going to struggle to build up its own institutions, but my personal view is that other people's legislation is probably a good start for developing your own.
ReplyDeleteI've heard it said that the EPO sometimes views itself as an arbiter between patentee and opponent(s) in opposition, rather than objectively judging patentability. That means decisions end up being a sort of compromise between the parties. Perhaps in practice that is the best way to keep the system functioning with maximum balance.
ReplyDelete